hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06328595 id: Cross sectional briefTitle: Muscular and Joint Symptoms in COVID-19 Patients: Insights From Syria overallStatus: COMPLETED date: 2022-04-22 date: 2023-05-04 date: 2023-08-20 date: 2024-03-25 date: 2024-03-26 name: Syrian Private University class: OTHER briefSummary: Observation study, shows the relation between musckeloskeletal symptoms with during and post Covid-19 infection, by asking participants questions about there age,job,which vaccination covid participants took, residual area, social status, number of time of covid-19 infection, number of joint affected and duration of joint pain and asking if there any malaise or fatigue conditions: Musculoskeletal Pain conditions: COVID-19 studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 1039 type: ACTUAL measure: The Demographic characteristics were classified into four groups: Gender, Residual area, education level. sex: ALL minimumAge: 18 Years maximumAge: 78 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mohamad Zaid Ahmad Abdalla city: Damascus country: Syrian Arab Republic lat: 33.5102 lon: 36.29128 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2023-09-24 uploadDate: 2024-03-22T04:16 filename: Prot_SAP_000.pdf size: 235804 hasResults: False
nctId: NCT06328582 id: Zhenjiu Post-stroke dysphagia briefTitle: Acupuncture Technique for Restoring Consciousness on Post-stroke Dysphagia overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-12 date: 2024-12 date: 2024-03-25 date: 2024-03-25 name: Copka Sonpashan class: OTHER_GOV briefSummary: This is a randomized controlled study, including post-stroke dysphagic patients. The participants were divided randomly into the experimental group and the control group. Both two groups were given routine treatment and swallowing rehabilitation training. Moreover, the experimental group was given Acupuncture Technique for Restoring Consciousness. Swallowing function will be compared before and after treatment. conditions: Dysphagia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: Routine rehabilitation training name: Acupuncture Technique for Restoring Consciousness combined with Scalp Acupuncture measure: Penetration-Aspiration Scale measure: Functional Oral Intake Scale measure: Gugging Swallowing Screen sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06328569 id: VR Wallenberg Syndrome briefTitle: Virtual Reality Therapy on Dysphagia in Wallenberg Syndrome overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-12 date: 2024-12 date: 2024-03-25 date: 2024-03-25 name: Copka Sonpashan class: OTHER_GOV briefSummary: The goal of this clinical trial is to learn about on dysphagia in wallenberg syndrome. The main questions it aims to answer are:
Participants received conventional dysphagia treatment and Virtual Reality Therapy once a day for 14 days. Researchers compared the control group to see the effect and mechanism of Virtual Reality Therapy. conditions: Wallenberg Syndrome studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 80 type: ESTIMATED name: Virtual Reality Therapy name: Conventional dysphagia treatment measure: standardized swallowing assessment measure: Murray secretion scale measure: penetration-aspiration scale measure: swallowing-quality of life sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06328556 id: Ultrasound-guided Botulinum briefTitle: Ultrasound-guided Botulinum Toxin Injection on Cricopharyngeal Muscle Dysfunction overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-12 date: 2024-12 date: 2024-03-25 date: 2024-03-25 name: Copka Sonpashan class: OTHER_GOV briefSummary: Ultrasound-guided injection is a visual, convenient, and radiation-free technique that allows real-time observation of the needle insertion process and drug injection location. The combination with a balloon for fixation further enhances the precision of the injection. In this study, the investigators employed ultrasound-guided injection combined with balloon localization for cricopharyngeal muscle botulinum toxin injection treatment and conducted clinical observations. conditions: Cricopharyngeal Achalasia studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: botulinum toxin type A name: Injection measure: functional oral intake scale measure: Penetration-Aspiration Scale measure: The Fiberoptic Endoscopic Dysphagia Severity Scale measure: Murray secretion scale sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06328543 id: N-20210046 4th project briefTitle: Itch Sensation Induced by Multiple Applications of Pruritogens (Temporal Summation) overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-12-31 date: 2026-12-31 date: 2024-03-25 date: 2024-03-25 name: Aalborg University class: OTHER briefSummary: In This experiment, the investigators would like to design a new itch model based on the temporal summation of pruritic stimuli. The hypothesis behind this study (temporal summation) is that two overlapped applications of pruritogens will result in a higher itch sensation compared with a single application. conditions: Histamine conditions: Cowhage studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: SINGLE_GROUP interventionModelDescription: The participants will randomly receive applications of cowhage and histamine primaryPurpose: BASIC_SCIENCE masking: SINGLE maskingDescription: Participant will be blinded about application of pruritogens whoMasked: PARTICIPANT count: 26 type: ESTIMATED name: Histamine name: Cowhage measure: Assessment of itch measure: Assessment of pain measure: Microvascular reactivity measure: Alloknesis measure: Mechanically evoked itch sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT hasResults: False
nctId: NCT06328530 id: N-20210046 3rd project briefTitle: Itch Sensation Induced by Simultaneous Application of Pruritogens (Spatial Summation) overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-12-31 date: 2026-12-31 date: 2024-03-25 date: 2024-03-25 name: Aalborg University class: OTHER briefSummary: In This experiment, the investigators would like to design a new itch model based on the spatial summation of pruritic stimuli. The hypothesis behind this study (spatial summation) is that two simultaneous applications of pruritogens will result in higher itch sensation compared with a single application of pruritogen. conditions: Histamine conditions: Cowhage studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: SINGLE_GROUP interventionModelDescription: The participants will randomly receive applications of cowhage and histamine. primaryPurpose: BASIC_SCIENCE masking: SINGLE maskingDescription: Participant will be blinded about application of pruritogens. whoMasked: PARTICIPANT count: 24 type: ESTIMATED name: Cowhage name: Histamine measure: Assessment of itch measure: Assessment of pain measure: Alloknesis measure: Mechanically evoked itch sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT hasResults: False
nctId: NCT06328517 id: 2023-305 briefTitle: The Influence of Nutritional Factors on the Prognosis of Liver Cirrhosis Patients and the Exploration of Predictive Models overallStatus: RECRUITING date: 2023-11-01 date: 2026-11-01 date: 2026-11-01 date: 2024-03-25 date: 2024-03-25 name: Juan Kang class: OTHER briefSummary: Cirrhosis is a progressive developing liver disease transforming normal hepatocytes into scar tissue with loss of function.The prevalence of cirrhosis has approximately tripled over the past two decades. With the increasing incidence of chronic liver disease, about 2 million people died from cirrhosis worldwide. Currently, D'Amico stage classification and Child-Pugh and Model for End-Stage Liver Disease (MELD) scores constitute the best tools to predict mortality in patients with Cirrhosis; however, one of their main limitations is the lack of evaluation of the nutritional and functional status. Patients with End-Stage Liver Disease (ESLD) have reduced nutritional intake, hypermetabolism, increased energy expenditure, impaired fasting adaptability, decreased hepatic glycogen reserves, and increased consumption of protein as the main energy donor that often lead to malnutrition, therefore, malnutrition is one of the most common complications in patients with Cirrhosis, is closely related to the increase in morbidity and mortality. Moreover, malnutrition is closely related to the high incidence of infection, ascites, hepatic encephalopathy, and hepatorenal syndrome, and is an independent risk factor affecting the survival rate of patients with End-Stage Liver Disease, including liver transplantation.
Therefore, malnutrition should be treated as equally important complications such as ascites and hepatic encephalopathy, and accurate screening, evaluation and appropriate nutritional intervention measures should be taken to improve the prognosis of patients with Cirrhosis. This study aims to establish a nomogram model about nutritional factors to predict the prognosis of patients with Cirrhosis, verify and optimize the model, through the establishment of the model, to more comprehensively evaluate and predict the prognosis of patients with Cirrhosis from the perspective of nutrition, to provide sufficient basis and lay a solid foundation for further nutritional intervention and improve patient prognosis. conditions: Cirrhosis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 300 type: ESTIMATED measure: Death measure: complication sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The Second Affiliated Hospital of Chongqing Medical University status: RECRUITING city: Chongqing state: Chongqing zip: 400000 country: China name: juan Kang role: CONTACT phone: +8613996112052 email: 68368892@qq.com lat: 29.56278 lon: 106.55278 hasResults: False
nctId: NCT06328504 id: Cashew Protocol briefTitle: Efficacy of Cashew Nut Protein Immunotherapy overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2026-04-21 date: 2027-04-21 date: 2024-03-25 date: 2024-03-25 name: Medical University of Warsaw class: OTHER briefSummary: It is a randomized, sigle-center, controlled trial to evaluate the effectiveness of oral immunotherapy with cashew protein compared with standard treatment (elimination diet) in pediatric patients with cashew allergy. conditions: Food Allergy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 39 type: ESTIMATED name: Cashew immunotherapy measure: Cashew full tolerance measure: Cashew partial tolerance measure: OIT safety measure: Wheal diamater in skin prick tests measure: SIgE and IgG 4 levels measure: BAT scores measure: Quality of life- FAQLQ measure: Air condensate sex: ALL minimumAge: 4 Years maximumAge: 17 Years stdAges: CHILD facility: Medical University of Warsaw city: Warsaw state: Mazowieckie zip: 02-091 country: Poland name: Agnieszka Szczukocka-Zych, MD role: CONTACT phone: +48 22 3179427 email: agnieszka.szczukocka-zych@wum.edu.pl lat: 52.22977 lon: 21.01178 hasResults: False
nctId: NCT06328491 id: OZUHN-014 id: 22-5325 type: OTHER domain: University Health Network briefTitle: Erdafitinib in Metastatic Steroid-cell Ovarian Cancer overallStatus: COMPLETED date: 2022-05-30 date: 2022-08-22 date: 2022-08-22 date: 2024-03-25 date: 2024-03-25 name: University Health Network, Toronto class: OTHER briefSummary: This is a single participant study of erdafitinib for the treatment of a patient with metastatic steroid-cell tumor of the ovary. conditions: Ovarian Cancer conditions: Steroid Cell Tumor, Malignant studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 1 type: ACTUAL name: Erdafitinib measure: Tumor response measure: Overall health status sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Princess Margaret Cancer Centre city: Toronto state: Ontario zip: M5G 2M9 country: Canada lat: 43.70011 lon: -79.4163 hasResults: False
nctId: NCT06328478 id: Predictors of AKI in PICU. briefTitle: Predictors of Acute Kidney Injury in Critically Ill Children Admitted to PICU. overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-04-01 date: 2025-05-01 date: 2024-03-25 date: 2024-04-16 name: Assiut University class: OTHER briefSummary: Predictors of Acute Kidney Injury in critically ill children admitted to PICU during one year. conditions: Acute Kidney Injury studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 100 type: ESTIMATED name: Observational prospective study. measure: Incidence of acute kidney injury and survival to discharge from the PICU. sex: ALL minimumAge: 1 Month maximumAge: 18 Years stdAges: CHILD stdAges: ADULT hasResults: False
nctId: NCT06328465 id: IEO 1108 briefTitle: fREEDOM: REsonance for Early Detection Of Breast Cancer Metastases acronym: fREEDOM overallStatus: RECRUITING date: 2019-11-22 date: 2028-12-31 date: 2028-12-31 date: 2024-03-25 date: 2024-03-25 name: European Institute of Oncology class: OTHER briefSummary: The aim of this study is to understand whether DWB-MRI (Diffusion Whole Body-Magnetic Resonance Imaging) is useful for early detection of locoregional or distant recurrence and whether early diagnosis influences the prognosis in high-risk populations thanks to the possibility of being able to use a more effective treatment. The primary objective is to evaluate 5-year overall survival (OS) in patients with Human Epidermal Growth Factor Receptor 2 positive (HER2+) or high-risk Triple Negative (TN) undergoing surveillance with DWB-MRI. conditions: Invasive Breast Cancer conditions: HER2-positive Breast Cancer conditions: Triple Negative Breast Cancer studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 145 type: ESTIMATED name: Diffusion whole body MRI measure: 5-year overall survival measure: Overall survival of patients underwent local treatment measure: Breast cancer specific survival measure: Safety of local treatment measure: Anxiety assessment measure: Health state assessment measure: Ability to Cope With Trauma assessment measure: Personality assessment measure: Acceptability and perception of DWB-MRI sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: European Institute of Oncology status: RECRUITING city: Milan zip: 20141 country: Italy name: Monica Iorfida, MD role: CONTACT phone: +390257489970 email: monica.iorfida@ieo.it name: Mara Negri role: CONTACT phone: +390257489536 email: mara.negri@ieo.it name: Monica Iorfida, MD role: PRINCIPAL_INVESTIGATOR lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06328452 id: MASLD briefTitle: Risk Factors and Impact MASLD in Patients With IBD acronym: MASLD overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-06-30 date: 2025-06-30 date: 2024-03-25 date: 2024-03-25 name: Assiut University class: OTHER briefSummary: Inflammatory bowel disease (IBD) is a chronic disease characterized by remitting and relapsing inflammation of the gastrointestinal tract. Crohn's disease (CD) and ulcerative colitis (UC) are the two main types of IBD and their incidence and prevalence are increasing.
Limited data are available on the frequency and risk factors of MASLD in Egyptian patients with IBD, and no published Egyptian study has addressed the clinical utility of serum steatosis markers in MASLD prediction in IBD population. Moreover, the impact of MASLD on IBD course is unclear. Therefore, we will conduct our study to shed some light on this issue. conditions: Metabolic Dysfunction-associated Steatotic Liver Disease studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 120 type: ESTIMATED name: FibroScan measure: Assess the prevalence and risk factors of metabolic dysfunction associated steatotic liver disease among patients attending inflammatory bowel disease outpatient clinic measure: Effect of metabolic dysfunction associated steatotic liver disease on inflammatory bowel disease course measure: Performance of serum steatosis markers in prediction of steatosis sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06328439 id: ANS014004-I-CN-01 briefTitle: A Study to Evaluate ANS014004 in Subjects With Locally Advanced or Metastatic Solid Tumors overallStatus: RECRUITING date: 2024-03-19 date: 2027-12-31 date: 2028-01-31 date: 2024-03-25 date: 2024-03-25 name: Avistone Biotechnology Co., Ltd. class: INDUSTRY name: Shanghai Chest Hospital name: Hunan Cancer Hospital name: Henan Cancer Hospital name: Zhejiang Cancer Hospital name: Peking University Cancer Hospital & Institute briefSummary: Brief Summary: This is a Phase I, first-in-human, open-label, multi-center study designed to explore the safety, tolerability, PK, and anti-tumor antitumor activity of ANS014004 monotherapy in subjects with locally advanced or metastatic solid tumors.
1, The dose-escalation part (Part 1) will consist of a single-dose period and a multiple-dose period (28 days per cycle), participants during dose escalation will receive a single dose of ANS014004 on Day 1 of the single-dose period in order to obtain complete PK parameters for the single dose. There will be a 7-day washout period between the single dosing period and the multiple dosing period at the same dose level. If no dose-limiting toxicity (DLT) occurs during the 7-day washout period, participants will begin Cycle 1 (28 days per cycle) multiple dosing treatment on Day 8, receiving ANS014004 once daily (QD). participants in the backfill cohort will enter the multiple dosing period directly. The specific dose which participant receives will depend on the different cohort assignments. The dose-escalation part (Part 1) will use the initial accelerated titration design (ATD) and the traditional "3 + 3" design to determine the MTD of ANS014004 in subjects with locally advanced or metastatic solid tumors.
All subjects will undergo imaging evaluations of their tumors every 8 weeks until disease progression is confirmed by the investigator, the subject begins new antitumor therapy, dies, is lost to follow-up, or withdraws from the study, whichever occurs first. conditions: Locally Advanced or Metastatic Solid Tumors studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SEQUENTIAL interventionModelDescription: Cohort1: 7.5mg Cohort2: 15mg Cohort3: 30mg Cohort4: 45mg Cohort5: 60mg primaryPurpose: TREATMENT masking: NONE count: 216 type: ESTIMATED name: ANS014004 measure: Incidence of Adverse Events (AEs) measure: Incidence of Serious Adverse Events (SAEs) measure: Incidence of dose-limiting toxicities (DLT) as defined in the protocol measure: Incidence of baseline laboratory finding, ECG and vital signs changes measure: Proportion of patients with radiological response (ORR) measure: Objective Response Rate (ORR) measure: Duration of Response (DoR) measure: Disease Control Rate (DCR) measure: Progression free Survival (PFS) measure: Overall Survival (OS) measure: Pharmacokinetics of ANS014004: Plasma PK concentrations measure: Pharmacokinetics of ANS014004: Area under the concentration time curve (AUC) measure: Pharmacokinetics of ANS014004: Maximum plasma concentration of the study drug (C-max) measure: Pharmacokinetics of ANS014004: Time to maximum plasma concentration of the study drug (T-max) measure: Pharmacokinetics of ANS014004: Clearance measure: Pharmacokinetics of ANS014004: Half-life sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Shanghai Chest Hospital status: RECRUITING city: Shanghai country: China name: Shun Lu, Ph.D role: CONTACT phone: +8618017321551 email: shunlu_shchest@sina.com lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06328426 id: Anti-osteoarthritis briefTitle: Vitamin D With Omega-3 or Metformin in Osteoarthritis overallStatus: NOT_YET_RECRUITING date: 2024-08 date: 2026-08 date: 2026-12 date: 2024-03-25 date: 2024-03-25 name: Assiut University class: OTHER briefSummary: To determine the efficacy of vitamin D with omega-3 or metformin for reducing knee symptoms and effusion synovitis in patients with symptomatic knee osteoarthritis. conditions: Osteoarthritis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 60 type: ESTIMATED name: Vitamin D name: Omega-3 name: Metformin name: Placebo measure: Effusion-synovitis volume on musculoskeletal ultrasound. sex: ALL minimumAge: 40 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06328413 id: KAEK-302 briefTitle: L-PRF vs PBM on Extraction Socket Healing overallStatus: COMPLETED date: 2020-04-20 date: 2021-06-21 date: 2021-09-21 date: 2024-03-25 date: 2024-03-25 name: Akdeniz University class: OTHER briefSummary: The aim of this study is to compare leukocyte and platelet-rich fibrin (L-PRF) and photobiomodulation (PBM) applications, which have been repeatedly reported to be superior to control groups, in terms of pain, soft tissue and bone healing in tooth extraction sockets. conditions: Healing Surgical Wounds conditions: Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Since the groups were formed on the same individual, only which side would be the PBM and which side would be the L-PRF group was determined by coin-flip method (simple randomization). primaryPurpose: TREATMENT masking: DOUBLE whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 34 type: ACTUAL name: photobiomodulation name: Leukocyte and Platelet Rich Fibrin measure: Newly formed bone (Healing at extraction sockets) measure: Soft tissue healing measure: Probing depth measure: Postoperative pain sex: ALL minimumAge: 18 Years maximumAge: 40 Years stdAges: ADULT facility: Akdeniz University city: Antalya state: Merkez zip: 07058 country: Turkey lat: 36.90812 lon: 30.69556 hasResults: False
nctId: NCT06328400 id: VV116-RSV-02 briefTitle: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Deuremidevir Hydrobromide for Suspension overallStatus: RECRUITING date: 2024-03-27 date: 2024-06-30 date: 2024-08-30 date: 2024-03-25 date: 2024-04-24 name: Vigonvita Life Sciences class: INDUSTRY briefSummary: This trial is a multi dose, randomized, double-blind, placebo-controlled, single center Phase I clinical study. The purpose of this study is to evaluate the safety, tolerability, and PK characteristics of Deuteromide Hydrobromide for Suspension administered multiple times in healthy volunteers. conditions: Respiratory Syncytial Virus Infections studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 24 type: ESTIMATED name: Deuremidevir Hydrobromide for Suspension name: Deuremidevir Hydrobromide for Suspension Placebo measure: Incidence of Treatment-Emergent Adverse Events measure: Cmax measure: Tmax measure: AUC0- t measure: AUC0-∞ measure: t1/2 sex: ALL minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: Hushan Hospital Fudan university status: RECRUITING city: Shanghai state: Shanghai zip: 201900 country: China name: Xiaojie Wu role: CONTACT phone: 13524686330 email: maomao_xj@163.com name: Jufang Wu role: CONTACT phone: 13816357099 email: 13816357099@163.com lat: 31.22222 lon: 121.45806 hasResults: False